TESARO Inc  

(Public, NASDAQ:TSRO)   Watch this stock  
Find more results for TIMOTHY PEARSON
61.73
+0.06 (0.10%)
Real-time:   3:59PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 59.25 - 63.63
52 week 22.15 - 64.97
Open 61.63
Vol / Avg. 747,617.00/617,859.00
Mkt cap 2.44B
P/E     -
Div/yield     -
EPS -4.79
Shares 39.99M
Beta     -
Inst. own 99%
May 14, 2015
TESARO Inc Annual Shareholders Meeting - 8:30AM EDT - Add to calendar
May 6, 2015
TESARO Inc at Deutsche Bank Health Care Conference - 2:10PM EDT - Add to calendar
May 5, 2015
TESARO Inc at Citi Midwest Healthcare Access Day Add to calendar
Apr 30, 2015
Q1 2015 TESARO Inc Earnings Call - 4:15PM EDT - Add to calendar
Apr 30, 2015
Q1 2015 TESARO Inc Earnings Release - 4:00PM EDT - Add to calendar
Apr 15, 2015
TESARO Inc at Jefferies Immuno-Oncology Summit
Mar 11, 2015
TESARO Inc at Barclays Healthcare Conference
Feb 19, 2015
Q4 2014 TESARO Inc Earnings Call - Webcast
Feb 19, 2015
Q4 2014 TESARO Inc Earnings Release
Feb 12, 2015
TESARO Inc at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -67.79% -85.62%
Return on average equity -131.61% -138.35%
Employees 108 -
CDP Score - -

Address

1000 Winter St Ste 3300
WALTHAM, MA 02451-1230
United States - Map
+1-339-9700900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company acquires, in-licenses and develops oncology product candidates and commercializes these products globally. The Company�s Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK).

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. President, Chief Operating Officer, Director
Age: 52
Bio & Compensation  - Reuters
Leon O. Moulder Jr. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy R. Pearson Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Joseph L. Farmer Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
James O. Armitage M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Arnold L. Oronsky Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Beth C. Seidenberg M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters